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Abstract
We examined the association between posttraumatic stress disorder (PTSD) and gene expression 
using whole blood samples from a cohort of trauma-exposed white non-Hispanic male veterans 
(115 cases and 28 controls). 10,264 probes of genes and gene transcripts were analyzed. We found 
41 that were differentially expressed in PTSD cases versus controls (multiple-testing corrected 
p<0.05). The most significant was DSCAM, a neurological gene expressed widely in the 
developing brain and in the amygdala and hippocampus of the adult brain. We then examined the 
41 differentially expressed genes in a meta-analysis using two replication cohorts and found 
significant associations with PTSD for 7 of the 41 (p<0.05), one of which (ATP6AP1L) survived 
multiple-testing correction. There was also broad evidence of overlap across the discovery and 
replication samples for the entire set of genes implicated in the discovery data based on the 
direction of effect and an enrichment of p<0.05 significant probes beyond what would be expected 
under the null. Finally, we found that the set of differentially expressed genes from the discovery 
sample was enriched for genes responsive to glucocorticoid signaling with most showing reduced 
expression in PTSD cases compared to controls.
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1. Introduction
The past decade of research on the genetics of PTSD has led to important discoveries 
through twin studies, candidate gene studies, genome-wide association studies (GWASs), 
methylation, and expression studies (see e.g. Guffanti et al., 2013; Logue et al., 2013; Mehta 
et al., 2013; Ressler et al., 2011; Sarapas et al., 2011; Segman et al., 2005; Xie et al., 2013; 
Yehuda et al., 2009; Zieker et al., 2007). Gene expression studies permit measurement of the 
downstream effects of genetic and epigenetic variation and can potentially lead to the 
identification of biomarkers not only for PTSD risk, (as with DNA loci), but potentially also 
of the actual manifestation of the syndrome. However, gene expression studies conducted to 
date have been limited by small samples and/or narrow scopes of analysis focused on a 
limited number of candidate genes. Other studies have used a transcriptome-wide approach 
to study PTSD expression. Here we use transcriptome-wide to indicate an examination of 
the expression of genes throughout the genome without prior hypothesis about the function 
of any associated genes, analogous to the way “genome-wide” is used to indicate an agnostic 
investigation of variants throughout the genome in a genetic association study. Four of the 
five published studies that have used expression arrays for transcriptome-wide investigations 
of RNA from peripheral blood were based on samples with less than 30 cases and 30 
controls (Sarapas et al., 2011; Segman et al., 2005; Yehuda et al., 2009). The exception was 
a study by Mehta et al. (2013) who examined PTSD-associated gene expression in 61 PTSD 
Logue et al. Page 2
















cases vs. 108 trauma-exposed controls. They found that genes and biological pathways 
implicated by comparing PTSD cases with childhood trauma to controls differed from those 
implicated when PTSD cases with only adult trauma were compared to controls. The 
investigators concluded from this that PTSD related gene expression changes might vary as 
a function of population (e.g. military vs. epidemiological samples) due to differences in 
type and/or developmental timing of trauma exposure.
Both transcriptome-wide and candidate gene expression studies of PTSD have implicated 
loci related to functioning of the hypothalamic-pituitary-adrenal axis and glucocorticoid 
signaling. For example, using a sample of 24 cases and 40 controls Ressler et al. (2011) 
found that expression levels of pituitary adenylate cyclase-activating polypeptide (PACAP)
—a gene involved in stress response—and its 38 residue peptide, PACAP38 (encoded by 
ADCYAP1), were associated with PTSD symptom severity and acoustic startle reflex in 
women. They then replicated this finding in an all-female sample of 30 cases and 45 
controls. Other candidate-gene expression studies have linked PTSD to expression of the 
brain-derived neurotrophic factor (BDNF) gene (see e.g. Dell'Osso et al., 2009; Matsuoka et 
al., 2013), which plays a role in glucocorticoid receptor (GR) regulation. Lambert et al. 
2013, Yehuda et al. 2009, and Sarapas et al. 2011 reported that the FK506 Binding Protein 5 
(FKBP5) gene, which is also implicated in moderating activity of the GR, was differentially 
expressed among participants with PTSD secondary to exposure to the World Trade Center 
attacks (n=15 PTSD cases and 20 controls in Yehuda et al., n=20 cases and 20 controls in 
Sarapas et al.). These two studies also showed that expression of the signal transducer and 
activator of transcription 5B (STAT5B) gene, which encodes a protein that inhibits the GR, 
was differentially expressed among participants with PTSD. FKBP5 and STAT5B were 
further implicated by Mehta et al (2011) in a candidate-gene study examining expression as 
a function of an FKBP5 polymorphism and PTSD severity (n=41 cases and 70 controls, 
FKBP5 interaction confirmed in an additional n=98 subjects; Mehta et al., 2011).
Building on previous work, the primary aim of this study was to perform a transcriptome-
wide examination of gene expression in PTSD. To increase power, we initially focused our 
attention on a homogeneous (in sex and ancestry) discovery sample of 143 trauma-exposed 
white non-Hispanic male veterans. Our second aim was to examine the robustness of the 
findings from the discovery sample and to look for evidence of replication in two additional 
(more diverse) samples: women and men of other ancestral groups from the veteran cohort 
(n=73) and an independent civilian cohort from the Detroit Neighborhood Health Study 
(DNHS; n=129). To our knowledge, when considered together (N = 345), these samples 
constituted the largest PTSD expression study conducted to date. A final aim was to 
examine the discovery sample for association between lifetime PTSD and expression of 
candidate genes previously identified as glucocorticoid responsive.
2. Materials and Methods
2.1 Samples
We examined expression in a clinical sample of 216 veterans (final n after quality filters and 
removal of subjects with missing data, see supplementary materials for details) enrolled in a 
study on the PTSD and its comorbidities. The recruitment methods and sample composition 
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have been described in detail elsewhere (Miller et al., 2012; Wolf et al., 2012). This is a 
subset of a larger cohort previously used in a genome-wide association study of PTSD 
(Logue et al., 2013). The research was approved and conducted under the oversight of the 
appropriate institutional review boards. All subjects were assessed with the Clinician 
Administered PTSD Scale for DSM-IV (CAPS-IV; Blake et al., 1990; Blake et al., 1995), 
which ascertains PTSD diagnosis per the DSM-IV diagnostic criteria. CAPS inter-rater 
reliability for the lifetime PTSD diagnosis, as determined through independent ratings of 
approximately one-third of the diagnostic interviews using videotape recordings, was 
excellent (kappa=0.87). The Traumatic Life Events Questionnaire (TLEQ; Kubany et al., 
2000) was used to assess exposure to different types of traumatic events in both childhood 
and adulthood. Ancestral population was determined by self-report and analysis of genome-
wide genotype data (described in detail in Logue et al., 2013).
The details of sample preparation, storage, and RNA extraction, RNA processing and data 
cleaning, including quality control (QC) and normalization, are presented in the 
supplementary materials. Expression was measured using the Illumina (San Diego, CA, 
USA) HumanHT12_v4 BeadChip which assesses 47,323 probes. Each probe measures the 
expression of a particular transcript (i.e. variant) of a particular gene. Approximately 40,000 
of these map to coding gene transcripts, 4,000 map to non-coding gene transcripts, while the 
remaining 3,000 probes map to confirmed RNA sequences that align to express sequence tag 
(EST) clusters. After QC filters based on the annotation from the Bioconductor 
illuminaHumanv4.db annotation (Barbosa-Morais et al., 2010; Dunning et al.) and removal 
of probes that were unexpressed in blood, 10,264 probes remained for analysis. The 
proportion of monocytes and lymphocytes were estimated for each individual using 
expression data from GEO (GSE50008) data using a linear model similar to those proposed 
elsewhere for cell-count estimation (Houseman et al., 2012; described in the Supplementary 
Methods). The sample was then split into a discovery cohort of white non-Hispanic (WNH) 
males (n=143, with 115 cases and 28 controls) and a replication cohort of the remaining 
subjects (n=73, with 51 cases and 22 controls), which included WNH females (n=17) as well 
as men and women of other ancestries or undetermined descent (n=56).
Replication was also examined in an independent sample from the Detroit Neighborhood 
Health Study (DNHS, n=129 with 64 cases and 65 controls; Goldmann et al., 2011; Uddin et 
al., 2010). Fifty-eight of these participants (45%) were male; the majority (n=108, or 84%) 
were African American. Expression was assessed using the same HumanHT12_v4 
BeadChip and analyzed using similar methods (see supplementary materials). Descriptive 
characteristics for each sample are presented in Supplementary Table 1.
2.2 Study Design and Analysis
Technical details of the analysis are in the Supplementary Methods. Briefly, Bioconductor’s 
limma package (Smyth, 2005) was used to test for association between lifetime PTSD and 
gene expression. Limma fits a linear regression model of gene expression as a function of 
PTSD and the included covariates. Age and estimated proportion of monocytes and 
lymphocytes were included as covariates in all analyses. Multiple-testing adjusted 
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significance (pcor) was computed using a Benjamini–Hochberg False Discovery Rate 
procedure (Benjamini and Hochberg, 1995).
We first examined all 10,264 blood-expressed probes that passed QC for association with 
PTSD in the discovery sample. Probes with pcor<0.05 were then examined in the two 
replication cohorts and in a meta-analysis across the two samples performed using the 
METAL (Willer et al., 2010) software. The p-value method of meta-analysis was used, 
which incorporates the p-value and direction of effect. We also performed a series of post-
hoc analyses examining the potential influences of genomic variation (single nucleotide 
polymorphisms; SNPs), comorbid depression, medication and substance abuse, and 
childhood vs. adult trauma. These analyses are described in the supplementary materials. We 
additionally examined the effect of PTSD severity (rather than the dichotomous diagnosis) 
in the model of gene expression.
INGENUITY’s (IPA; www.ingenuity.com) network analysis was used to identify biological 
links between a “target set” of 90 genes associated with PTSD in the discovery sample at the 
pcor<0.10 (Supplementary Table 3) level. IPA’s network analysis accepts an input of a target 
list of genes and creates a number of local networks of up to 35 genes which both maximize 
the number of target genes and the number of connections between them, adding other non-
target genes/molecules as necessary. The network analysis optimizes the connectivity of the 
genes in the list, but it should be stressed that the network is not necessarily restricted to or 
representative of a single biological pathway.
The possible involvement of the differentially expressed genes in particular biological 
process or disease pathways was examined using the Gene-Set Enrichment Analysis 
(GSEA) software (Mootha et al., 2003; Subramanian et al., 2005) and INGENUITY’s 
Canonical Pathway and Disease/Biological Function analyses. These tools are similar, in 
that they search for evidence of enrichment of genes in particular gene-set lists. GSEA looks 
for enrichment corresponding to GO categories and KEGG pathways, and the INGENUITY 
tools look for enrichment of curated gene-sets created according to INGENUITY’s 
knowledge base.
In addition to these curated lists, we compared our “target set” of 90 top genes to a list of 
probes for GR-regulated genes derived from results of an in vivo dexamethasone stimulation 
experiment that identified GR-regulated transcripts in peripheral blood. In that study, gene 
expression levels in peripheral blood were compared pre- and 3 hours post- dexamethasone 
administration in 160 Caucasian males, (93 healthy controls and 71 male in-patients with 
depressive disorders). Recruitment strategies, participant characteristics and blood sample 
collection, processing and analysis was described in (Menke et al., 2012) and (Hennings et 
al., 2009). Total RNA was extracted from PaxGene RNA tubes using standard procedures 
and hybridized to Illumina HumanHT-12 v3.0 Expression BeadChips (Illumina, Inc., San 
Diego, CA, USA). Quality control and data analysis was performed in R as described in 
(Menke et al., 2012). The position of the probes and possible SNPs within these sequences 
were annotated using ReMOAT version August 2009 (http://remoat.sysbiol.cam.ac.uk/, 
Barbosa-Morais et al., 2010). These expression data have been deposited in the NCBI Gene 
expression omnibus (GSE46743). In these data, 4,375 expression probes that showed an 
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absolute fold change of 1.3 or greater from pre- to post-dexamethasone administration in at 
least 20% of all samples and were classified therefore as “glucocorticoid responsive”. See 
Supplementary Table 5 for a complete listing. We then used this list to evaluate if the set of 
PTSD-associated genes in this study was enriched for glucocorticoid-responsive genes using 
both Fisher’s exact test and a permutation test (with 10,000 replicates).
Finally, we examined the discovery dataset for association between lifetime PTSD and 
expression of previously implicated candidate genes. We focused on GWAS-implicated 
genes (Guffanti et al., 2013; Logue et al., 2013; Xie et al., 2013), published candidate genes 
(based on Skelton et al. 2012 review), and other loci which had been implicated in 
expression studies of PTSD (Ressler et al., 2011; Uddin et al., 2011; Yehuda et al., 2009; 
Zieker et al., 2007). This yielded 14 probes of interest: one each for COMT, ADCYAP1, 
ADCYAP1R1, RORA, STAT5B, and BDNF, and two probes each for TXNRD1, IL16, S1PR1, 
and NR3C1 (see Supplementary Table 2 for details). Probes were not available for several of 
the genes of interest either because they were not included on the microarray (AC068718.1), 
because probes for these genes failed to pass quality filters based on the 
illuminaHumanv4.db annotation (FKBP5- poor mapping quality and secondary matches, 
NPY-poor mapping quality, DBH-poor mapping quality, DAT1-poor mapping quality and 
secondary matches, 5-HTR2A -poor mapping quality and secondary matches, RGS2-
secondary matches, MAN2C1-secondary matches, IL18-poor mapping quality and secondary 
matches, and SOD1-secondary matches), or because they were not expressed in blood at 
sufficient levels (TLL1, DRD2, GABARA2, SLC6A4, CASP2, and TET1). For this portion of 
the analysis, the FDR-corrected p-value (pcor) was adjusted for the examination of these 14 
probes.
3. Results
3.1 Transcriptome-wide Association Analyses
The transcriptome-wide analysis of 10,264 probes yielded 41 probes with multiple testing-
corrected associations with PTSD (Table 1; pcor<0.05). All but one of the implicated genes 
(TBC1D15) had lower expression in PTSD cases than controls (t<0 in Table 1). The most 
significant association was with the Down syndrome cell adhesion molecule (DSCAM) gene 
(ILMN_1658420; p=2.77×10−6, pcor=0.010). Expression of DSCAM was lower in cases than 
controls (Figure 1). A heatmap of expression for the 41 PTSD-associated genes is presented 
in Figure 2a. The bar between the heatmap and the dendogram represents PTSD status, with 
yellow signifying PTSD cases and blue signifying controls. The dendogram at the top of the 
figure represents an unsupervised (i.e. without including information about PTSD status) 
hierarchical clustering of the subjects based on expression values. Subjects are divided into 
two groups based on the first split in the dendogram. Group 1 consisted of 34 subjects 
(58.8% PTSD) who showed higher expression of most PTSD-associated genes. Group 2 
consisted of 109 subjects with lower expression levels and a greater proportion of cases with 
PTSD (95 of 109 or 87.2%, OR=4.68, p=0.00082). Results of the transcriptome-wide 
analysis of PTSD severity were less significant; no probes were significantly associated with 
PTSD severity (pcor>.05).
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We then examined these 41 probes for association with PTSD in both the VA replication 
sample and the DNHS cohorts. In the VA sample, expression of DSCAM and four other 
genes were significant (p from 0.0037 to 0.039), but none survived correction for multiple 
testing (pcor>0.05). However, the direction of association was consistent across the VA 
discovery and VA replication samples, agreeing for 39 of the 41 probes, which is more than 
would be expected by chance (p=3.9×10−10). In the DNHS replication sample, 4 genes 
(9.8%) were associated with PTSD (p from 0.00036 to 0.047), and expression of the 
ATPase, H+ transporting, lysosomal accessory protein 1-like (ATP6AP1L) gene remained 
associated after multiple-testing correction (pcor=0.015). Again, the direction of the 
associations in the DNHS sample was more consistent with the discovery data than would 
be expected by chance (30 out of 41, p=0.0022).
Meta-analysis of the replication cohorts showed that the association between ATP6AP1L 
expression and PTSD was strengthened compared to what had been observed in DNHS 
alone (p=0.00019), and ATP6AP1L remained significant after multiple testing correction. 
(pcor=0.0078). In addition, 7 genes, more than would be expected by chance (17%, 
p=0.0039), were associated with PTSD at the pmeta<0.05 level (Table 1). All 7 genes 
replicating at the p<0.05 level had lower expression in PTSD cases compared to controls. A 
heatmap of expression for these 7 genes is presented in Figure 2B and shows clearer 
distinction between PTSD cases and controls compared with the set of 41 probes that were 
identified using only the discovery sample. Using this set of replicating genes, there is still a 
high (n=19) and a low (n=124) expression group. The high expression group (Group 1 in 
Figure 2B) contains fewer PTSD cases (42%) than the low expression group (Group 2; 
86%). Hence, clustering based on expression of these 7 genes is strongly associated with 
PTSD (OR=8.46, p=6.72×10−5).
3.2 Pathway and Network Analyses
INGENUITY’s canonical pathway analyses of the top 90 (pcor<0.10) “target list” genes 
from our discovery-sample identified no pathways that were significantly enriched for the 
PTSD-associated genes at the multiple-testing corrected significant level. Similarly, analysis 
of the log fold-change values in GSEA did not identify any multiple-testing correction 
significant GO terms or KEGG pathways. However, INGENUITY’s Disease and Biological 
Function tool identified several pathways enriched for our target genes, including pathways 
involved in Neurological Disease, (i.e., Ataxia and Neurodegeneration; see Table 3).
We then evaluated whether the target list genes were enriched for genes related to the GR 
signaling pathway by comparing the target list to the experimentally derived set of 
glucocorticoid-responsive probes. Of the 4,375 GR-responsive probes, 2,703 passed quality 
filters and were analyzed in the VA sample. Hence, 26% of the 10,264 analyzed probes were 
identified as “glucocorticoid responsive”. In comparison, 35 (39%) of our top 90 probes 
were on the list (see Supplementary Table 3) suggesting that our list of differentially 
expressed genes contained a greater proportion of glucocorticoid-responsive genes than 
would be expected by chance (Fisher's exact p=0.0017, permutation test p=0.0059). Of the 
35 target-list genes that were also glucocorticoid-responsive, 27 (77%) had lower expression 
in cases compared to controls and 8 (23%) had higher expression in cases compared to 
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controls. When we compared these effects to the fold-change estimates from the 
dexamethasone stimulation experiment, we found perfect concordance. That is, All 27 genes 
with lower expression in PTSD cases had higher expression after dexamethasone 
administration and all 8 genes with higher expression in PTSD cases had lower expression 
after dexamethasone administration (Figure 3A), which is highly unlikely to be due to 
chance (sign-test significance based on Fisher’s exact p=4.25×10−8).
We then explored the relationship between the PTSD-associated genes and the GR pathway 
using the INGENUITY network analysis to identify possible biological links between the 90 
target-list genes. INGENUITY’s top network, that is, the network with the highest 
proportion of target genes, is presented in Figure 3B. This network included 21 genes from 
our target list and 14 genes/molecules to increase connectivity. Of the added genes/
molecules, half (7) were related to GR signaling. The GR signaling molecules are 
highlighted in purple in Figure 3B.
3.3 Candidate Genes and Covariates
Analysis of probes for the 14 candidate genes implicated in previous PTSD studies showed 
that the GR gene (NR3C1), BDNF, and the thioredoxin reductase 1 (TXNRD1) gene were 
significantly associated with PTSD in our discovery cohort (pcor<0.05 when adjusted for 14 
candidate genes examined; Table 2). For both BDNF and NR3C1, expression was lower in 
PTSD cases than controls while the opposite was true for TXNRD1 (Figure 1).
Finally, examination of potential confounders (i.e., depression, medication use, and 
substance abuse, as described in the Supplementary Materials) revealed no evidence of 
significant effects of these factors. We also examined the potential role of genomic (SNP) 
variation might play and identified several expression quantitative trait loci (eQTLs), for 
SMIM1, ATP6AP1L, and BDNF (see Supplementary Results and Supplementary Table 4). 
However, none of these eQTLs were associated with PTSD, and the associations between 
PTSD and expression of these genes remained significant when these SNPs were included as 
predictors in the same analysis.
4. Discussion
Transcriptome-wide analysis of gene expression levels in peripheral blood drawn from a 
sample of white non-Hispanic veterans (115 PTSD cases and 28 controls) revealed that 
expression levels for 41 of 10,264 probes differed significantly as a function of PTSD 
diagnosis. A replication meta-analysis showed that 7 of these 41 genes were associated with 
the disorder at the p<0.05 level, with one of them surviving multiple-testing correction. 
Despite differences in the discovery and replication samples, including sex differences, 
recruitment differences, and the ratio of cases to controls (see Supplementary Materials for 
details), we found broad evidence of overlap across the discovery and replication samples 
for the set of genes implicated in the discovery sample based on the direction of effect and 
enrichment of p<0.05 associations beyond what would be expected by chance. If the 
discovery and replication samples were more closely matched, this agreement might have 
been greater.
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Several findings suggested that differential expression of genes observed in PTSD cases is 
(at least in part) related to glucocorticoid signaling. When we compared our 90 most 
differentially expressed genes to a list of genes whose expression is altered by 
dexamethasone administration (Hennings et al., 2009; Menke et al., 2012), we found that a 
greater proportion of our differentially expressed genes were on this list than would be 
expected by chance, as were two of our most differentially expressed genes: DSCAM 
(differentially expressed in the discovery sample) and ATP6AP1L (differentially expressed 
in both the discovery and replication analyses). For the genes on our top list which where 
altered by dexamethasone, genes with lower expression in PTSD cases had increased 
expression after administration of dexamethasone and vice versa (Figure 3A). INGENUITY 
network analysis independently confirmed that many of the PTSD-associated genes in this 
study, though not classified as GR signaling genes themselves, interact with elements of the 
GR signaling pathway (Figure 3B). Finally, our candidate-gene analysis of loci previously 
implicated in PTSD also revealed reduced expression of the GR gene (NR3C1).
Together, these findings contribute to a vast body of research implicating abnormalities in 
HPA-axis reactivity and GR sensitivity and signaling in PTSD. NR3C1 regulation has been 
linked to the presence of developmental adversity in both mouse experiments and humans 
(see e.g. Champagne and Curley, 2009; Perroud et al., 2011). Mouse models of GR 
deficiency have also implicated Nr3c1 in behavioral traits and emotional stability (e.g. 
Boyle et al., 2006; Pepin et al., 1992; Tronche et al., 1999). A transcriptome-wide study of 
the differences between stress vulnerable and resilient rats (Daskalakis et al., 2014) found 
that transcription factors predicted to regulate their differentially expressed genes were 
consistently related to the GR signaling network and NR3C1 was a predicted transcription 
factor for expression changes observed in blood and brain tissue from the amygdala and 
hippocampus. The latter raises the intriguing possibility that the NR3C1 expression 
differences observed in this study might reflect NR3C1 regulated alterations in the brain.
The most significant differentially expressed gene in our discovery sample, DSCAM, is 
known to play a role in neural development, including axon guidance and branching and 
synapse maturation (Schmucker and Chen, 2009) and it is likely responsible for some of the 
neurological features of Down syndrome (Yamakawa et al., 1998). The DSCAM association 
should be considered preliminary, however, as it was only associated at the p<0.05 level in 
the VA replication cohort and not significantly associated with the disorder in the DNHS 
replication sample.
One gene survived multiple-testing correction in our replication meta-analysis: ATP6AP1L. 
ATP6AP1L is the largely uncharacterized paralogue of ATP6AP1. ATP6AP1 is part of an 
enzyme that assists in the acidification of organelles and may play a role in regulation of 
neuroendocrine responses through the acidification of neuroendocrine secretory granules 
(Supek et al., 1994).
It is interesting to note that of the genes whose expression levels were associated with PTSD 
in this study, one is known to be imprinted (MAGEL2; Boccaccio et al., 1999), one has an 
imprinted isoform (INPP5F; Choi et al., 2005), and two more (IRX1 and PTP4A3) are 
predicted to be imprinted (Luedi et al., 2007). Imprinted genes are regulated epigenetically 
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with many involved in embryonic development and neurobehavioral traits (Tycko and 
Morison, 2002). While it is not likely that the mechanism of imprinting is itself is related to 
the expression differences that we found between PTSD cases and controls, expression 
differences in these genes may point to a role for DNA methylation or other epigenetic 
mechanisms in PTSD and its expression signature.
Analysis of candidate genes previously implicated in PTSD revealed differential expression 
of BDNF, TXNRD1 and, as noted above, the GR gene (NR3C1). BDNF plays a role in 
learning, memory, and fear extinction (Andero and Ressler, 2012). Lower BDNF expression 
in serum has been linked to untreated depression (Molendijk et al., 2013). Studies have also 
linked BDNF expression levels to PTSD, but findings have been inconsistent with some 
reporting increased BDNF expression in PTSD cases and others showing the opposite (see 
e.g. Dell'Osso et al., 2009; Matsuoka et al., 2013). In this study, we found that PTSD cases 
had lower BDNF expression than trauma-exposed controls (probe ILMN_1761910, logFC= 
−0.24, p= 0.0014; Figure 1). The inconsistency across studies of BDNF expression may be a 
result of the different tissues studied, differences in study population, or differences in the 
duration of symptoms since the trauma.
The other candidate gene that was differentially expressed, TXNRD1, encodes a protein, 
thioredexin, which plays an important role in responding to oxidative stress by mounting an 
antioxidant response. Levels of the protein are thought to index oxidative stress (Nakamura, 
2005) and so the elevated levels observed in PTSD cases versus controls in this study is 
consistent with growing evidence for the role of oxidative stress in disorders of the trauma 
and stress-related spectrum (Miller & Sadeh, 2014). TXNRD1, is also associated with 
neuroprotection in individuals with neurodegenerative disorders and has been found to index 
neurocognitive impairment among individuals with schizophrenia (Zhang et al., 2013).
There are several limitations that should be kept in mind when interpreting our results. As 
these data were cross sectional, we cannot determine whether the expression differences 
represent expression signature of past or current PTSD, or if it is it is marker of a pre-trauma 
vulnerability to the development of PTSD. We examined expression in whole blood, and not 
all genes and transcripts are expressed in blood. Additionally, whole blood is itself contains 
a heterogeneous mixture of cell types, each of which may have unique expression patterns. 
We recognize that differences in cell proportions may be caused by differences in the 
proportion of cell types if not properly controlled. To address this issue, we estimated the 
proportion of different cell types and included these estimates as covariates in our analysis 
models. Additionally, we cannot determine specificity of expression changes to any 
particular cell type. Studies in other tissues, or a specific cell type isolated from whole blood 
may not show the same effects. Our statistical adjustment for different cell type proportions 
included an adjustment for white blood cell proportions but did not adjust for RNA from 
reticulocytes. This leaves open the possibility that the proportion of reticulocytes (i.e., 
immature red blood cells) in the sample could explain observed associations. We find this 
unlikely, as broad agreement was observed between the VA discovery and replication 
samples and the DNHS replication sample, and reticulocyte RNA was removed from the 
DNHS-study samples. While we have evidence of broad agreement across the discovery and 
replication samples, only one specific gene replicated at a multiple-testing corrected level. 
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This may be due to the noted difference in sample preparation, or some of the differentially 
expressed genes may be population-specific and not universally generalizable. A final 
limitation was that we did not have qPCR validation of the results in our discovery sample.
To conclude, this study identified a set of genes whose expression was associated with 
PTSD. We obtained evidence of partial replication in results from two additional samples. 
Unsupervised clustering of the expression levels of replicating genes yielded a classification 
that was strongly associated with PTSD (OR > 8). This suggests that as expression study 
sample sizes increase, it may be possible in the future to develop reliable biomarkers of 
PTSD risk and/or diagnostic status using expression probes. We also found that many of our 
PTSD-associated effects involved lower expression levels for genes related to the GR 
pathway, possibly reflecting HPA axis dysregulation. Prior studies have indicated that 
lymphocyte GRs are increased in PTSD cases (Yehuda et al., 1996a; Yehuda et al., 1991; 
Yehuda et al., 1993; Yehuda et al., 1996b) resulting in enhanced suppression of the HPA 
axis in response to GR activation. The suppressed expression of our top genes may be a 
reflection of these alterations, although the genes we identified here, including DSCAM and 
ATP6AP1 have not been previously linked to PTSD. Examining the function of these 
peripheral and downstream affiliates of the GR signaling pathway may lead to identification 
of novel biomarkers of PTSD and potential targets for treatment.
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Boxplots of DSCAM, ATP6AP1L, NR3C1, BDNF, and TXNRD1 expression in the white 
non-Hispanic male discovery cohort of n=143 cases and 28 controls as a function of PTSD 
status.
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Heatmap of expression in the white non-Hispanic male discovery cohort of n=143 cases and 
28 controls, for A) the 41 significant (pcor<0.05) probes in the discovery sample and B) the 7 
genes with pmeta<0.05 in the replication meta-analysis. Rows represent genes, columns 
represent subjects. The degree of expression from high to low is represented by the colors 
white and yellow on the high end, and orange and red on the low end. The colored bar above 
the heatmap represents PTSD status, with blue=no PTSD, yellow=Lifetime PTSD.
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Analyses of the “target list” of 90 genes implicated in PTSD at the pcor<0.10 level which 
implicate glucocorticoid receptor signaling. A) A plot of the fold-change estimates for the 
35 PTSD-associated “target list” genes identified as GR regulated in the dexamethasone 
stimulation experiment. Fold change estimates from the dexamethasone experiment are 
presented on the x axis and the fold-change estimates from the comparison of male PTSD 
cases and controls in the white non-Hispanic discovery sample are presented on the y axis. 
B) INGENUITY-generated network of interacting genes with glucocorticoid receptor 
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signaling genes/molecules highlighted in purple. The grey shapes indicate genes and 
molecules from the target list, while open shapes indicate that a gene was added by 
INGENUITY to increase network connectivity.
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Table 2
Previously implicated PTSD genes which are differentially expressed in the white non-Hispanic male 
discovery cohort of n=143 cases and 28 controls. (Pcor<.05).*,**
Gene IlluminaID t p pcor***
BDNF ILMN_1761910 −3.25 0.0014 0.010
NR3C1 ILMN_1668525 −3.31 0.0012 0.010
TXNRD1 ILMN_2324421 2.83 0.0053 0.025
*
No probes were significant for RORA, COMT, ADCYAP1, ADCYAP1R1, NPSR1, STAT5B, IL16, or S1PR1.
**
The following genes did not have probes which passed quality checks or were not expressed at sufficient levels to be included in the analysis: 
TLL1, AC068718.1, FKBP5, NPY, DBH, DRD2, DAT1, SLC6A4, 5-HTR2A, GABRA2, RGS2, MAN2C1, IL18, CASP2, SOD1, and TET1.
***
Here, pcor represents correction for 14 probes targeting previously implicated PTSD genes.
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Table 3
Top disease and biological function gene categories according to INGENUITY analysis of the 90 “target” 
genes* with pcor<0.10 in the association analysis of the white non-Hispanic male discovery cohort of n=143 
PTSD cases and 28 controls.


















−5 0.025 FGF18, FGF23, FOSL2
Neurodegeneration of
nervous tissue 3.78×10







−5 0.025 FGF18, FGF23, FOSL2
Proliferation of
Chondrocytes 2.59×10
−3 0.046 FGF18, FGF23, FOSL2
Abnormal morphology
of atlas. 3.01×10





−3 0.036 KCNJ10, SLC4A7
Degeneration of
supporting cell layer of
inner ear
5.23×10−4 0.046 CLRN1, SLC4A7
Usher syndrome 3A 3.91×10−3 0.046 CLRN1
*
The complete list of target genes is presented in Supplementary Table 3.
**
pcor is the Benjamini Hochberg FDR corrected p-value.
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